The Viral Vector and Plasmid DNA Manufacturing Market refers to the industrial processes and services that enable the production of viral vectors and plasmid DNA used in gene therapies, vaccine ...

Ottawa, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The global viral vector and plasmid DNA manufacturing market size was valued at USD 7.19 billion in 2024 and is expected to be worth around USD 46.02 billion ...

North America dominated the viral vector & plasmid DNA manufacturing market with a revenue share in 2024. Asia Pacific is expected to grow at the fastest CAGR in the market during the forecast period.

Cell and gene therapies have brought great advances to the treatment of severe diseases previously deemed untreatable. Despite commercial and clinical success of AAV-based gene therapies (seven ...

CDMOs are building cell and viral vector manufacturing facilities left and right, but Harvard says it just isn’t enough, at least to serve the Boston biotech hub. That is why a host of public and ...

The global viral vector manufacturing market is projected to expand at a robust CAGR of approximately 20% over the forecast period, supported by multiple transformative forces reshaping the ...

New state-of-the-art facility in Plainville, Mass., to manufacture materials central to production of gene-based therapeutics “Plainville is an impressive addition to our pharma services network as we ...

Vector BioMed raised $15 million in a first round of funding as the startup looks to help fill a big gap in the manufacture of cell and gene therapies. The latest entry into the CDMO viral vector ...

A global contract developer says it is among the first to offer a standardized approach to manufacturing adeno-associated viruses (AAVs) and lentiviruses (LVVs) for advanced therapies. AGC Biologics ...

MALVERN, Pa.--(BUSINESS WIRE)--Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing ...

Vector Biolabs, a custom design and manufacturing service provider for AAV and adenovirus viral vectors announced the completion of a facility expansion to meet growing demand. The purpose of the ...